N/A
N=39,374
Investigating Healthcare Disparities in Vitiligo
Vitiligo
Bottom Line
View on ClinicalTrials.gov: NCT06097494 ↗Enrolled (actual)
39,374
Serious AEs
—
Results posted
Mar 2025
Primary outcome: Primary: Risk of Depression Within Patients With Vitiligo — 1412; 5395 Events
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- No intervention (Other)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Momentum Data
- Primary completion
- Jul 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Risk of Depression Within Patients With Vitiligo |
1412; 5395 | — |
| PRIMARY Risk of Anxiety Within Patients With Vitiligo |
708; 2430 | — |
| PRIMARY Risk of Depression or Anxiety Within Patients With Vitiligo |
1614; 6064 | — |
| SECONDARY Primary Care Encounters |
134207; 439633 | — |
| SECONDARY Dermatology Referrals |
20 | — |
| SECONDARY Mental Health Referrals |
311; 1191 | — |
| SECONDARY Unemployment |
111; 436 | — |
| SECONDARY Time Off Work |
746; 2472 | — |
| SECONDARY Sleep Disturbance |
318; 1102 | — |
Summary
Vitiligo is an acquired, non contagious skin disorder characterised by depigmented patches of skin that may appear in a localised or very generalised distribution, and affecting 0.5-2.0% of the global population.There are however, limited population-based studies on the burden of vitiligo and disparities across people of different ethnicities and deprivation.
The overall purpose of this study is to provide an estimate of the lifetime risk of vitiligo in the population overall and by sociodemographic subgroups. Moreover, to do a subgroup analysis in the vitiligo population to identify health-related disparities across people in different sex, age, deprivation and ethnicity. A detailed understanding of the burden of disease in different sociodemographic groups is vital to plan resource provision.
Eligibility Criteria
Inclusion Criteria
- The cohort for the endpoint analysis will consist of all adults and adolescents (aged 13+) contributing to OPCRD during the study period (2004-2020).
- The cohort for the lifetime risk analysis will consist of all people contributing to OPCRD during the study period.
- The vitiligo cohort consists of people newly diagnosed with vitiligo at any point during the study period.
Exclusion Criteria
- People with the alternative non-vitiligo diagnoses (other hypopigmenting conditions).
- People with vitiligo diagnosis within 6 months of practice registration.
- People without vitiligo with less than 1 year of follow up within the dataset.
- People over the age of 95 (for those reaching age 95 during the follow up period follow up was censored at age 95).
- People who have opted out of record sharing.
Data sourced from ClinicalTrials.gov (NCT06097494). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.